News | Atrial Fibrillation | July 12, 2017

Wearable Cardiac Monitors Are Effective for Tracking Atrial Fibrillation Following Ablation

Cardea Solo wearable cardiac monitor eliminates service centers and put control of patient data, analysis in the hands of doctors

Cardiac Insight FDA-approved Cardea Solo wearable ECG monitoring system

July 12, 2017 — Cardiac Insight Inc., a U.S. developer of wearable medical devices and diagnostic software, announced its FDA-approved Cardea Solo ECG monitoring system is available for diagnosing atrial fibrillation (AF or AFib) following cardiac ablation. The company’s cardiac monitoring device supports a recent formal consensus statement by experts from 11 leading international cardiology organizations that recognizes the use of wearable sensing devices in patients who have undergone AFib ablation procedures.

The formal acknowledgement of wearable sensors was one of a series of recommendations for treating the millions of patients who have AF, a common rhythm disorder that increases the risk of heart failure and stroke. The expert consensus statement was collectively developed by the Heart Rhythm Society (HRS), European Heart Rhythm Association, European Cardiac Arrhythmia Society, among several others.

Cardiac ablation is an invasive procedure that is used to eliminate atrial fibrillation. Among its many applications, Cardea Solo is a new, distinctive, cost-effective and timely solution for monitoring the effectiveness and results of atrial fibrillation ablation.

“The societies’ recommendations will advance the treatment of atrial fibrillation, including the use of wearable sensors like Cardea Solo for diagnosing heart rhythm disorders and monitoring patients after atrial fibrillation ablation,” said Robert Hauser, M.D., FACC, FHRS, HRS past-president and senior consulting cardiologist (retired), Minneapolis Heart Institute. “It is vital to detect and treat atrial fibrillation before it causes a stroke or heart failure. Cardea Solo provides the information doctors need in a more timely and cost-effective manner than currently offered by other wearable sensors.”

Cardea Solo is the first and only wearable cardiac sensor to eliminate the need for expensive and time-consuming third-party service centers and puts the control of patient data, analysis and processing in the hands of physicians and their staffs.

The device sensor records ECG data and patient symptoms. The wearable sensor is small, lightweight (approximately the weight of three quarters), lead-less, water-resistant and single-use disposable. Patients can wear Cardea Solo comfortably under their clothing for up to seven days and maintain their normal daily activities. The design and ease-of-use also makes it more likely patients will wear the sensor and capture meaningful data for enhanced evaluation.

For more information: www.cardiacinsightinc.com

Related Content

News | Atrial Fibrillation

May 17, 2022 — Results of a new study reveal Black patients hospitalized with atrial fibrillation (AF) are under ...

Home May 17, 2022
Home
News | Atrial Fibrillation

May 17, 2022 — Results from a new study show success of intended same day discharge (SDD) improves over time for ...

Home May 17, 2022
Home
News | Atrial Fibrillation

May 17, 2022 — On the heels of its landmark valvular heart disease (VHD) prevalence abstract published in Journal of the ...

Home May 17, 2022
Home
News | Atrial Fibrillation

May 2, 2022 – Johnson & Johnson MedTech have announced that Biosense Webster, Inc., a worldwide leader in the science ...

Home May 02, 2022
Home
News | Atrial Fibrillation

April 12, 2022 – iRhythm Technologies, Inc., a leading digital healthcare solutions company focused on the advancement ...

Home April 12, 2022
Home
News | Atrial Fibrillation

April 1, 2022 — Cardiologs announced a poster presentation at the 2022 American College of Cardiology (ACC) meeting in ...

Home April 01, 2022
Home
News | Atrial Fibrillation

March 9, 2022 – Point-of-care screening for atrial fibrillation (A-fib) using a new generation of handheld ...

Home March 09, 2022
Home
News | Atrial Fibrillation
February 28, 2022 – iRhythm Technologies, Inc., a leading digital healthcare solutions company focused on the ...
Home February 28, 2022
Home
News | Atrial Fibrillation
February 16, 2022 – A new way of treating arrhythmias, including atrial fibrillation (AF) — the most common heart ...
Home February 16, 2022
Home
Feature | Atrial Fibrillation

Improved short-term monitoring methods for patients with stroke risk can increase early detection of atrial fibrillation ...

Home December 07, 2021
Home
Subscribe Now